| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3120ae9cab5bb4831f0cc16288966367 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-177
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 |
| filingDate |
2017-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a49163a95e7a575938eb52bb8b9d668b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17ea823af5f0e39dc3feb42b52e6f5e6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d66059caa231bbb0f3976a0b06d6067
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a1d4af99aa5432aa5c4be8802be55a03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4821342d612e35406478646ac0b71d56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_73477a00a5b96f7993b4a04129bd855b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_daa66cc56588f122bf03e732f213e97b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d9f6637dbf57d2d7a793819fee1d67e8 |
| publicationDate |
2020-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10822385-B2 |
| titleOfInvention |
EGF(A) analogues with fatty acid substituents |
| abstract |
The invention relates to compounds derived from the EGF(A) domain of LDL-R, in particular compounds comprising a peptide analogue of the wild-type EGF(A) (LDL-R(293-332)) sequence and at least one substituent comprising at least one fatty acid group. The invention also relates to a pharmaceutical composition thereof and use a medicament. The novel EGF(A) compounds of the invention are useful as treatment e.g. in the field of cholesterol lowering, dyslipidaemia and cardiovascular disease. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11130794-B2 |
| priorityDate |
2016-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |